Page last updated: 2024-10-27

foscarnet and Exanthem

foscarnet has been researched along with Exanthem in 2 studies

Foscarnet: An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpesviruses and HIV.
phosphonoformic acid : Phosphoric acid in which one of the hydroxy groups is replaced by a carboxylic acid group. It is used as the trisodium salt as an antiviral agent in the treatment of cytomegalovirus retinitis (CMV retinitis, an inflamation of the retina that can lead to blindness) and as an alternative to ganciclovir for AIDS patients who require concurrent antiretroviral therapy but are unable to tolerate ganciclovir due to haematological toxicity.

Research Excerpts

ExcerptRelevanceReference
"Although foscarnet is a promising alternative for the treatment of cytomegalovirus (CMV) infection, its toxicity can be significant in patients with advanced age."7.74Reduced dose of foscarnet as preemptive therapy for cytomegalovirus infection following reduced-intensity cord blood transplantation. ( Hori, A; Kami, M; Kato, D; Kusumi, E; Masuoka, K; Matsumura, T; Miyakoshi, S; Morinaga, S; Murashige, N; Narimatsu, H; Shibata, T; Taniguchi, S; Wake, A; Yuji, K, 2007)
"Although foscarnet is a promising alternative for the treatment of cytomegalovirus (CMV) infection, its toxicity can be significant in patients with advanced age."3.74Reduced dose of foscarnet as preemptive therapy for cytomegalovirus infection following reduced-intensity cord blood transplantation. ( Hori, A; Kami, M; Kato, D; Kusumi, E; Masuoka, K; Matsumura, T; Miyakoshi, S; Morinaga, S; Murashige, N; Narimatsu, H; Shibata, T; Taniguchi, S; Wake, A; Yuji, K, 2007)
"Skin rash are common in immunocompromised patients, particularly after bone marrow transplantation."1.38Human Herpesvirus-6 cytopathic inclusions: an exceptional and recognizable finding on skin biopsy during HHV6 reactivation after autologous stem-cell transplantation. ( Battistella, M; Bouaziz, JD; Deau, B; Fornecker, L; Houhou, N; Janin, A; Legoff, J; Roux, J; Thieblemont, C, 2012)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Roux, J1
Battistella, M1
Fornecker, L1
Legoff, J1
Deau, B1
Houhou, N1
Bouaziz, JD1
Thieblemont, C1
Janin, A1
Narimatsu, H1
Kami, M1
Kato, D1
Matsumura, T1
Murashige, N1
Kusumi, E1
Yuji, K1
Hori, A1
Shibata, T1
Masuoka, K1
Wake, A1
Miyakoshi, S1
Morinaga, S1
Taniguchi, S1

Other Studies

2 other studies available for foscarnet and Exanthem

ArticleYear
Human Herpesvirus-6 cytopathic inclusions: an exceptional and recognizable finding on skin biopsy during HHV6 reactivation after autologous stem-cell transplantation.
    The American Journal of dermatopathology, 2012, Volume: 34, Issue:6

    Topics: Antiviral Agents; Biopsy; Cytopathogenic Effect, Viral; Exanthema; Foscarnet; Hematopoietic Stem Cel

2012
Reduced dose of foscarnet as preemptive therapy for cytomegalovirus infection following reduced-intensity cord blood transplantation.
    Transplant infectious disease : an official journal of the Transplantation Society, 2007, Volume: 9, Issue:1

    Topics: Adolescent; Adult; Aged; Antigens, Viral; Antiviral Agents; Cord Blood Stem Cell Transplantation; Cy

2007